These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3838634)

  • 1. Maxzide or Dyazide: a cautionary note.
    Kaplan NM
    Ann Intern Med; 1985 May; 102(5):717. PubMed ID: 3838634
    [No Abstract]   [Full Text] [Related]  

  • 2. A new antihypertensive agent: Maxzide (75 mg triamterene/50 mg hydrochlorothiazide).
    Blume CD; Williams RL
    Am J Med; 1984 Nov; 77(5A):52-8. PubMed ID: 6388327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function.
    Williams RL; Thornhill MD; Upton RA; Blume C; Clark TS; Lin E; Benet LZ
    Clin Pharmacol Ther; 1986 Aug; 40(2):226-32. PubMed ID: 3731685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the anti-hypertensive effectiveness of two triameterene/hydrochlorothiazide combinations: Maxzide versus Dyazide.
    Casner PR; Dillon KR
    J Clin Pharmacol; 1990 Aug; 30(8):715-9. PubMed ID: 2401750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide.
    Blume CD; Williams RL; Upton RA; Lin ET; Benet LZ
    Am J Med; 1984 Nov; 77(5A):59-61. PubMed ID: 6496560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
    Knauf H; Möhrke W; Mutschler E; Völger KD
    Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.
    Upton RA; Williams RL; Lin ET; Gee WL; Blume CD; Benet LZ
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):575-86. PubMed ID: 6533293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a fixed combination with propranolol, hydrochlorothiazide and triamterene.
    Felder K; Geissler HE; Hiemstra S; Mutschler E; Schäfer M; Ziegler E
    Arzneimittelforschung; 1979; 29(11):1746-52. PubMed ID: 543886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of kidney stones.
    Ettinger B
    JAMA; 1982 Oct; 248(16):1971. PubMed ID: 7120618
    [No Abstract]   [Full Text] [Related]  

  • 10. Preliminary observations on dissolution and bioavailability of triamterene-hydrochlorothiazide combination products.
    Shah VP; Walker MA; Prasad VK; Lin J; Knapp G; Cabana BE
    Biopharm Drug Dispos; 1984; 5(1):11-9. PubMed ID: 6704502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition.
    Farge D; Turner MW; Roy DR; Jothy S
    Am J Kidney Dis; 1986 Dec; 8(6):445-9. PubMed ID: 3812475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption and disposition of a new low-dose combination formulation of hydrochlorothiazide and triamterene.
    Williams RL; Lin ET; Liang-Gee W; Blume CD; Benet LZ
    Biopharm Drug Dispos; 1990 Apr; 11(3):233-43. PubMed ID: 2328310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and bioequivalence of a brand-name and a generic triamterene-hydrochlorothiazide combination product.
    Sharoky M; Perkal M; Tabatznik B; Cane RC; Costello K; Goodwin P
    Clin Pharm; 1989 Jul; 8(7):496-500. PubMed ID: 2752698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relation between the hypotensive effect of triampur and its pharmacokinetics in patients with hypertension].
    Kuznetsov GP; Lebedev PA
    Kardiologiia; 1986 Mar; 26(3):49-52. PubMed ID: 3712933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amantadine-dyazide interaction.
    Wilson TW; Rajput AH
    Can Med Assoc J; 1983 Nov; 129(9):974-5. PubMed ID: 6671185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic diabetes insipidus associated with Dyazide (triamterene-hydrochlorothiazide).
    Macleod MD; Bell GM; Irvine WJ
    Br Med J (Clin Res Ed); 1981 Oct; 283(6300):1155-6. PubMed ID: 6794799
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of bioavailability on dose-response relationships.
    Goldman P
    Am J Med; 1984 Nov; 77(5A):47-51. PubMed ID: 6496559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a diuretic (Dyazide) in the treatment of Menière's disease. A double-blind cross-over placebo-controlled study.
    van Deelen GW; Huizing EH
    ORL J Otorhinolaryngol Relat Spec; 1986; 48(5):287-92. PubMed ID: 3537899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of a hydrochlorothiazide plus triamterene combination (Dyazide) and atenolol in the treatment of patients with mild hypertension: a multicentre study in general practice.
    Philip IG; Qureshi SM; Richards HH; Sharma SK; Wright FG; Young PH; Rowley-Jones D
    Br J Clin Pract; 1987 Oct; 41(10):947-53. PubMed ID: 3333144
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral triamterene disposition.
    Sörgel F; Hasegawa J; Lin ET; Williams RL
    Clin Pharmacol Ther; 1985 Sep; 38(3):306-12. PubMed ID: 4028626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.